1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Awards Supporting Cutting-Edge Technologies for Translational Science (ASCETTS) (R21 Clinical Trials Not Allowed) is sponsored by National Center for Advancing Translational Sciences (NCATS) / NIH. This program supports early-stage proof of concept and exploratory technology development for high-risk, high-reward projects that can transform or significantly improve the efficiency of therapeutic development.
Get alerted about grants like this
Save a search for “National Center for Advancing Translational Sciences (NCATS) / NIH” or related topics and get emailed when new opportunities appear.
Search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
NOT-TR-25-009: Notice of Extension for PAR-25-157 Awards Supporting Cutting-Edge Technologies for Translational Science (ASCETTS) (R21 Clinical Trials Not Allowed) Notice of Extension for PAR-25-157 Awards Supporting Cutting-Edge Technologies for Translational Science (ASCETTS) (R21 Clinical Trials Not Allowed) December 10, 2024 - Awards Supporting Cutting-Edge Technologies for Translational Science (ASCETTS) (R21 Clinical Trials Not Allowed).
See NOFO PAR-25-157 National Center for Advancing Translational Sciences ( NCATS ) The purpose of this Notice is to inform applicants that effective immediately the National Center for Advancing Translational Sciences ( NCATS ) is extending PAR-25-157 Awards Supporting Cutting-Edge Technologies for Translational Science (ASCETTS) (R21 Clinical Trials Not Allowed) by one Council round.
The following text in bold and italics has been updated to reflect the extension: Part 1.
Overview Information Application Due Dates Review and Award Cycles New Renewal / Resubmission / Revision (as allowed) AIDS Scientific Merit Review Advisory Council Review Earliest Start Date June 19, 2025 June 19, 2025 Not Applicable October 2025 January 2026 April 2026 June 18, 2026 June 18, 2026 Not Applicable October 2026 January 2027 April 2027 Expiration Date: June 19, 2026 All other aspects of the NOFO remain the same.
Please direct all inquiries to: National Center for Advancing Translational Sciences (NCATS) Weekly TOC for this Announcement NIH... Turning Discovery Into Health ®
According to the current listing, eligibility includes: Eligibility is broad and includes various domestic U. S. Confirm the full requirements in the official notice before applying.
The current listing shows $275,000 over 2 years. Verify award ceilings, matching requirements, and allowable costs in the official notice.
The published deadline was June 18, 2026, which has passed. Check the official notice for any future application windows before investing time in a proposal.
Awards Supporting Cutting-Edge Technologies for Translational Science (ASCETTS) (R21 Clinical Trials Not Allowed) is funded by National Center for Advancing Translational Sciences (NCATS) / NIH. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
Advance from NIH SBIR Phase I to Phase II with tips on demonstrating feasibility, building a commercialization plan, and securing $1M in funding.
Read articleNIH's June 1 omnibus reset added Direct-to-Phase II to the STTR program for the first time. The change compresses university spinouts' funding timeline from three years to fifteen months, but the 30% research-institution subaward, feasibility-evidence rules, and IP licensing mechanics are not yet sorted at most universities.
Read articleNIH committed $402 million across 601 multiyear-funded grants in the first eight months of FY 2026 — more than four times the pace of two years ago. The mechanism front-loads obligations into a single fiscal year, leaving less budget for new project starts and squeezing FY 2026 success rates. What researchers and institutions should be doing now.
Read article